Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

molecule in the ITI/Takeda collaboration, ITI-214.  The Company has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression and cardiovascular disease.

Forward-looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected timing of the commencement of trading on the OTCQB of our common stock, the results of our Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia, and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated;  product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for further clinical trials, development and commercialization of our product candidates; the costs associated with our research, development and other activities may exceed those that we estimate; the conduct and results of preclinical and clinical studies of our product candidates may pose ch
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  MedSpring Urgent Care, an ... clinic at 517 S. Lamar Blvd., Austin, TX ... clinic is located on the southeast corner of Barton Springs ... from 9 a.m. - 9 p.m. daily, including weekends and holidays. ... Texas, Central Austin , Anderson Mill , ...
(Date:7/28/2014)... 28, 2014  TNI BioTech, Inc. (OTCQB: TNIB) ... on the development, marketing and distribution of opioid-related ... proxy materials with the Securities and Exchange Commission ... Shareholders to be held on Thursday, September 4, ... record date for determining those shareholders eligible to ...
(Date:7/28/2014)... BEIJING , July 28, 2014 Concord ... (NYSE: CCM ), a leading specialty hospital ... of radiotherapy and diagnostic imaging centers in ... 2014, its Board of Directors declared a special cash ... American Depositary Share ("ADS")) on the Company,s outstanding ordinary ...
Breaking Medicine Technology:MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2
... The Iowa Health Information Technology Regional Extension Center (HITREC) has selected ... record (EHR), practice management and interoperability solution PrimeSuite® , as ... federal Department of Health and Human Services (HHS) REC healthcare ... , ...
... PRINCETON, N.J. , July 12 ... Co., Ltd., has launched AFC Medirepair® with Signum,s ... .  Arazine™ is the first compound from Signum,s ... pipeline of Signal Transduction Modulators (STMs). The DRx ...
Cached Medicine Technology:Iowa Regional Extension Center Selects Greenway EHR Solutions 2Iowa Regional Extension Center Selects Greenway EHR Solutions 3Iowa Regional Extension Center Selects Greenway EHR Solutions 4Iowa Regional Extension Center Selects Greenway EHR Solutions 5Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 2Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 3
(Date:7/28/2014)... (July 28, 2014) -- Researchers from The University of Texas ... and other institutions have identified a combination of pills that ... of the drugs sofosbuvir and simeprevir, with or without ribavirin, ... well tolerated by patients, according to the study published today ... conducted in the U.S. , Eric Lawitz, M.D., clinical ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... The Oneida Indian Nation today announced that golf ... PGA TOUR players will be teeing up with four-time ... for the seventh annual Notah Begay III Foundation (NB3F) ... Atunyote® Golf Club on Wednesday, August 27, the star-studded ... Walker, Jonas Blixt, Angel Cabrera and Louis Oosthuizen, in ...
(Date:7/28/2014)... San Jose, CA (PRWEB) July 28, 2014 ... and family life Americans face today, BlogHer, The Center ... up to launch “Make Life Work,” a campaign to ... faced by families across the U.S. The joint initiative ... by Stacy Morrison, Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, ...
(Date:7/28/2014)... 28, 2014 According to a ... Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology (CVD, ... (Power, Opto-electronic), Application, and Geography-2013-2020", published by MarketsandMarkets, ... CAGR of 12.63% from 2014 to 2020 and ... market data tables and 88 figures spread through ...
Breaking Medicine News(10 mins):Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 2Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 3Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 4
... In a case study that illustrates the need for people ... themselves from pets, a woman with numbness in her feet caused ... Jack Russell terrier chewed off part of her slightly infected big ... the Journal of the American Podiatric Medical Association . ...
... -- The drug telaprevir (Incivek) provides a dramatic improvement in ... infection, says an international team of investigators led by Dr. ... Their study, published in today,s edition of the New ... agent for patient use by the U.S. Food and Drug ...
... HealthDay Reporter , WEDNESDAY, June 22 (HealthDay News) -- Silicone-gel ... of women with the devices requiring removal within 10 years ... And "the longer a woman has the implants, the more ... for the Center for Devices and Radiological Health at the ...
... Medical Center (GUMC) have defined, for the first time, three ... sounds such as speech and discovered that they are ... the June 22 issue of the Journal of Neuroscience ... the help of 13 human volunteers who spent time in ...
... , WEDNESDAY, June 22 (HealthDay News) -- Although depression ... giving birth, those who have had an eating disorder or ... the condition, according to a new study. This ... routine part of prenatal care, concluded researchers from the University ...
... WEDNESDAY, June 22 (HealthDay News) -- People who are born ... anxiety and mood disorders due to the impact that city ... emotion and stress, a new international study indicates. The ... of life for city dwellers, according to the researchers. ...
Cached Medicine News:Health News:Cautionary tale for people with diabetes: Dog consumed part of a sleeping patient's toe 2Health News:NEJM study: New drug represents breakthrough in treatment of hepatitis C 2Health News:NEJM study: New drug represents breakthrough in treatment of hepatitis C 3Health News:FDA: Breast Implants Basically Safe, But Won't Last a Lifetime 2Health News:FDA: Breast Implants Basically Safe, But Won't Last a Lifetime 3Health News:Researchers identify components of speech recognition pathway in humans 2Health News:Researchers identify components of speech recognition pathway in humans 3Health News:Eating Disorders May Raise Risk of Depression in Pregnancy 2Health News:City Living Tied to More Anxiety, Mood Disorders 2
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
... an immunochromatography based one step in vitro ... Opiates and its metabolite in human urine,specimens. ... above a cut-off level of 300 ng/mL,can ... evaluated in the point of care location ...
... test is an immunochromatography based one ... for qualitative determination of Methamphetamine in ... of 1000 ng/mL. This assay has ... of care,location and is for use ...
Medicine Products: